Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Ranibizumab
Related studies linked through entity extraction aliases.
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
- Status
- COMPLETED
- Phase
- PHASE3
Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
- Status
- UNKNOWN
- Phase
- PHASE4
Ranibizumab for Diabetic Traction Retinal Detachment
- Status
- COMPLETED
- Phase
- PHASE2
Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion
- Status
- COMPLETED
- Phase
- PHASE3
Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)
- Status
- UNKNOWN
- Phase
- PHASE3
HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
- Status
- COMPLETED
- Phase
- PHASE1
Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE2
Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)
- Status
- COMPLETED
- Phase
- PHASE3
LUCAS (Lucentis Compared to Avastin Study)
- Status
- COMPLETED
- Phase
- PHASE4
Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion
- Status
- UNKNOWN
- Phase
- PHASE2
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
- Status
- TERMINATED
- Phase
- PHASE2
A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy
- Status
- COMPLETED
- Phase
- PHASE2
Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study
- Status
- COMPLETED
- Phase
- PHASE2
Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
- Status
- COMPLETED
- Phase
- PHASE1
Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2